Unicycive Therapeutics
UNCY
23 hedge funds and large institutions have $9.5M invested in Unicycive Therapeutics in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 5 closing their positions.
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
10.63% less ownership
Funds ownership: 61.14% → 50.51% (-11%)
70% less capital inflows, than outflows
Capital inflows: $985K | Capital outflows: $3.24M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$785K |
| 2 |
LPL Financial
San Diego,
California
|
+$83.6K |
| 3 |
BlackRock
New York
|
+$51K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$32K |
| 5 |
Scientech Research LLC
Jersey City,
New Jersey
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BVF Inc
San Francisco,
California
|
-$1.39M |
| 2 |
RA Capital Management
Boston,
Massachusetts
|
-$824K |
| 3 |
Nantahala Capital Management
New Canaan,
Connecticut
|
-$507K |
| 4 |
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$303K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$95.8K |
UNCY Hedge Fund Activity: Q2 2024 in Review
23 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2024, worth a combined $9.5M — down 70% from $31.6M a quarter earlier.
Fund positioning in UNCY was balanced in Q2 2024: 5 funds opened new positions, 5 closed out, 6 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $785K. The largest seller was BVF Inc, cutting an estimated $1.39M.
- 23 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $9.5M of Unicycive Therapeutics stock for Q2 2024, down 70% quarter-over-quarter.
- 5 funds opened new Unicycive Therapeutics positions in Q2 2024 and 5 closed out, a net change of 0 holders.
- The largest Unicycive Therapeutics buyer in Q2 2024 was Vanguard Group, an estimated $785K added.
- The largest Unicycive Therapeutics seller in Q2 2024 was BVF Inc, an estimated $1.39M sold.
Based on aggregated 13F filings for Q2 2024.